tradingkey.logo
tradingkey.logo
Search

Bio-Techne Corp

TECH
Add to Watchlist
71.000USD
0.0000.00%
Close 06/26, 16:00ETQuotes delayed by 15 min
11.07BMarket Cap
100.60P/E TTM

TradingKey Stock Score of Bio-Techne Corp

Currency: USD Updated: 2026-06-26

Key Insights

Bio-Techne Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 6 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 67.80.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Bio-Techne Corp's Score

Industry at a Glance

Industry Ranking
6 / 387
Overall Ranking
43 / 4566
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

20°C

Very Low
Very High
Positive

Bio-Techne Corp Highlights

StrengthsRisks
Bio-Techne Corporation develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, advanced tissue-based in-situ hybridization assays and instrumentation for spatial genomic and tissue biopsy analysis and genetic and oncology kits for research and clinical applications. Its product portfolio and application enable scientific investigations into biological processes and molecular diagnostics and progression of specific diseases.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 68.69%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 68.69%.
Overvalued
The company’s latest PE is 100.60, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 178.19M shares, increasing 0.00% quarter-over-quarter.
Held by Lee Ainslie
Star Investor Lee Ainslie holds 5.14M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.56.

Analyst Rating

Based on 18 analysts
Buy
Current Rating
67.801
Target Price
-4.10%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

FAQs

How does TradingKey generate the Stock Score of Bio-Techne Corp?

The TradingKey Stock Score provides a comprehensive assessment of Bio-Techne Corp based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Bio-Techne Corp’s performance and outlook.

How do we generate the financial health score of Bio-Techne Corp?

To generate the financial health score of Bio-Techne Corp, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Bio-Techne Corp's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Bio-Techne Corp.

How do we generate the company valuation score of Bio-Techne Corp?

To generate the company valuation score of Bio-Techne Corp, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Bio-Techne Corp’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Bio-Techne Corp’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Bio-Techne Corp.

How do we generate the earnings forecast score of Bio-Techne Corp?

To calculate the earnings forecast score of Bio-Techne Corp, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Bio-Techne Corp’s future.

How do we generate the price momentum score of Bio-Techne Corp?

When generating the price momentum score for Bio-Techne Corp, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Bio-Techne Corp’s prices. A higher score indicates a more stable short-term price trend for Bio-Techne Corp.

How do we generate the institutional confidence score of Bio-Techne Corp?

To generate the institutional confidence score of Bio-Techne Corp, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Bio-Techne Corp’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Bio-Techne Corp.

How do we generate the risk management score of Bio-Techne Corp?

To assess the risk management score of Bio-Techne Corp, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Bio-Techne Corp’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Bio-Techne Corp.
KeyAI